Skip to main content
OpenTrials

Clinical trial condition

Lung Diseases, Obstructive

Explore clinical trials studying Lung Diseases, Obstructive. Study availability and eligibility vary by location and protocol.

7,978 public trials 744 recruiting studies
Refine in advanced search Browse all conditions

Lung Diseases, Obstructive trial results

Completed

Soundbite Crossing System Peripheral First in Man

NCT03013088

Conditions
Arterial Occlusive Diseases, Arteriosclerosis, Atherosclerosis, +20 more
Locations
  • CHUM - Centre Hospitalier de l'Université de Montreal - Hôtel-Dieu Montreal, Quebec, Canada
  • CHUS - Centre Hospitalier Universitaire de Sherbrooke - Freurimont Sherbrooke, Quebec, Canada
View Trial Details
Completed

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

NCT01159912

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Montgomery, Alabama, United States
  • GSK Investigational Site Green Valley, Arizona, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
View all 82 locations
View Trial Details
Completed

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

NCT01072149

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site DeLand, Florida, United States
  • GSK Investigational Site Orlando, Florida, United States
  • GSK Investigational Site Madisonville, Kentucky, United States
  • GSK Investigational Site Columbus, Ohio, United States
View Trial Details
Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

NCT01627327

Conditions
Cardiovascular Diseases, Chronic Disease, Disease Attributes, +6 more
Locations
  • GSK Investigational Site Newport Beach, California, United States
  • GSK Investigational Site Coeur d'Alene, Idaho, United States
  • GSK Investigational Site Charlotte, North Carolina, United States
  • GSK Investigational Site Cincinnati, Ohio, United States
View all 54 locations
View Trial Details
Completed

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02152605

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Upland, California, United States
  • GSK Investigational Site Clearwater, Florida, United States
  • GSK Investigational Site Saint Charles, Missouri, United States
View all 54 locations
View Trial Details
Completed

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01009463

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Peoria, Arizona, United States
View all 188 locations
View Trial Details

Related conditions